These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 35768763

  • 1. Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system.
    Ozawa T, Namkoong H, Takaya R, Takahashi Y, Fukunaga K, Enoki Y, Taguchi K, Kizu J, Matsumoto K, Hasegawa N.
    BMC Infect Dis; 2022 Jun 29; 22(1):580. PubMed ID: 35768763
    [Abstract] [Full Text] [Related]

  • 2. A survey of clarithromycin monotherapy and long-term administration of ethambutol for patients with MAC lung disease in Japan: A retrospective cohort study using the database of health insurance claims.
    Iwao T, Kato G, Ito I, Aramaki E, Kuroda T.
    Pharmacoepidemiol Drug Saf; 2020 Apr 29; 29(4):427-432. PubMed ID: 31876044
    [Abstract] [Full Text] [Related]

  • 3. Impact of rifampicin on the pharmacokinetics of clarithromycin and 14-hydroxy clarithromycin in patients with multidrug combination therapy for pulmonary Mycobacterium avium complex infection.
    Iketani O, Komeya A, Enoki Y, Taguchi K, Uno S, Uwamino Y, Matsumoto K, Kizu J, Hasegawa N.
    J Infect Chemother; 2022 Jan 29; 28(1):61-66. PubMed ID: 34706852
    [Abstract] [Full Text] [Related]

  • 4. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
    Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M.
    J Infect Chemother; 2006 Aug 29; 12(4):195-202. PubMed ID: 16944258
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease.
    Hasegawa N, Nishimura T, Ohtani S, Takeshita K, Fukunaga K, Tasaka S, Urano T, Ishii K, Miyairi M, Ishizaka A.
    Chest; 2009 Dec 29; 136(6):1569-1575. PubMed ID: 19542259
    [Abstract] [Full Text] [Related]

  • 6. The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease.
    Fujita M, Kajiki A, Tao Y, Miyazaki M, Ouchi H, Harada E, Ikegame S, Matsumoto T, Uchino J, Watanabe K, Nakanishi Y.
    J Infect Chemother; 2012 Apr 29; 18(2):146-51. PubMed ID: 21927844
    [Abstract] [Full Text] [Related]

  • 7. [Strategies for Mycobacterium avium complex infection control in Japan: how do they improve the present situation?].
    Ogawa K, Sano C.
    Kekkaku; 2013 Mar 29; 88(3):355-71. PubMed ID: 23672176
    [Abstract] [Full Text] [Related]

  • 8. [Non-tuberculous mycobacteriosis. What has been coming out].
    Kajiki A.
    Kekkaku; 2011 Feb 29; 86(2):113-25. PubMed ID: 21404655
    [Abstract] [Full Text] [Related]

  • 9. Adverse reactions associated with long-term drug administration in Mycobacterium avium complex lung disease.
    Kamii Y, Nagai H, Kawashima M, Matsuki M, Nagoshi S, Sato A, Kohno S, Ohgiya M, Ohta K.
    Int J Tuberc Lung Dis; 2018 Dec 01; 22(12):1505-1510. PubMed ID: 30606324
    [Abstract] [Full Text] [Related]

  • 10. Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease.
    Adachi Y, Tsuyuguchi K, Kobayashi T, Kurahara Y, Yoshida S, Kagawa T, Hayashi S, Suzuki K.
    J Infect Chemother; 2020 Jul 01; 26(7):676-680. PubMed ID: 32171660
    [Abstract] [Full Text] [Related]

  • 11. Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy.
    Ito Y, Miwa S, Shirai M, Kanai M, Fujita K, Ohba H, Iwaizumi E, Oshima T, Kojima S, Suda T, Hayakawa H.
    Respir Med; 2020 Aug 01; 169():106025. PubMed ID: 32442113
    [Abstract] [Full Text] [Related]

  • 12. First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease.
    Fukushima K, Kitada S, Komukai S, Kuge T, Matsuki T, Kagawa H, Tsujino K, Miki M, Miki K, Kida H.
    Sci Rep; 2021 Jan 13; 11(1):1178. PubMed ID: 33441977
    [Abstract] [Full Text] [Related]

  • 13. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period.
    Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M.
    J Infect Chemother; 2012 Aug 13; 18(4):436-43. PubMed ID: 22205543
    [Abstract] [Full Text] [Related]

  • 14. [A study of adverse drug reactions in the treatment of pulmonary Mycobacterium avium complex disease].
    Ichiki H, Watanabe A, Ueda S, Sato C, Abe M.
    Kekkaku; 2012 Jul 13; 87(7):487-90. PubMed ID: 22993889
    [Abstract] [Full Text] [Related]

  • 15. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.
    Kim HJ, Lee JS, Kwak N, Cho J, Lee CH, Han SK, Yim JJ.
    BMC Pulm Med; 2019 Nov 11; 19(1):212. PubMed ID: 31711459
    [Abstract] [Full Text] [Related]

  • 16. Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular/bronchiectatic Mycobacterium avium complex lung disease with rifampicin, ethambutol and clarithromycin (iREC): study protocol.
    Nakagawa T, Hashimoto H, Yagi M, Kogure Y, Sekimizu M, Saito AM, Ogawa K, Inoue Y.
    BMJ Open Respir Res; 2019 Nov 11; 6(1):e000434. PubMed ID: 31258920
    [Abstract] [Full Text] [Related]

  • 17. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
    Kadota T, Matsui H, Hirose T, Suzuki J, Saito M, Akaba T, Kobayashi K, Akashi S, Kawashima M, Tamura A, Nagai H, Akagawa S, Kobayashi N, Ohta K.
    BMC Infect Dis; 2016 Jan 27; 16():31. PubMed ID: 26818764
    [Abstract] [Full Text] [Related]

  • 18. Small-Cell Lung Cancer Comorbid with Pulmonary Mycobacterium avium Infection: A Case Report.
    Yamasaki M, Funaishi K, Saito N, Sakamoto KI, Ishiyama S, Kawamoto K, Matsumoto Y, Matsumoto N, Taniwaki M, Ohashi N, Hattori N.
    Chemotherapy; 2018 Jan 27; 63(5):257-261. PubMed ID: 30466088
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study.
    Miwa S, Shirai M, Toyoshima M, Shirai T, Yasuda K, Yokomura K, Yamada T, Masuda M, Inui N, Chida K, Suda T, Hayakawa H.
    Ann Am Thorac Soc; 2014 Jan 27; 11(1):23-9. PubMed ID: 24298907
    [Abstract] [Full Text] [Related]

  • 20. Treatment Outcomes after Discontinuation of Ethambutol due to Adverse Events in Mycobacterium avium Complex Lung Disease.
    Kwon YS, Kwon BS, Kim OH, Park YE, Shim TS, Chong YP, Jo KW.
    J Korean Med Sci; 2020 Mar 09; 35(9):e59. PubMed ID: 32141249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.